VivoSim Labs, Inc. (NASDAQ:VIVS) — Market Cap & Net Worth
Market Cap & Net Worth: VivoSim Labs, Inc. (VIVS)
VivoSim Labs, Inc. (NASDAQ:VIVS) has a market capitalization of $3.74 Million ($3.74 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28882 globally and #5670 in its home market, demonstrating a -2.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VivoSim Labs, Inc.'s stock price $1.44 by its total outstanding shares 2599800 (2.60 Million). Analyse how efficiently does VivoSim Labs, Inc. generate cash to see how efficiently the company converts income to cash.
VivoSim Labs, Inc. Market Cap History: 2025 to 2026
VivoSim Labs, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $4.71 Million to $3.74 Million (0.00% CAGR).
VivoSim Labs, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VivoSim Labs, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
32.68x
VivoSim Labs, Inc.'s market cap is 32.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $4.71 Million | $144.00K | -$2.49 Million | 32.68x | N/A |
Competitor Companies of VIVS by Market Capitalization
Companies near VivoSim Labs, Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to VivoSim Labs, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
VivoSim Labs, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, VivoSim Labs, Inc.'s market cap moved from $4.71 Million to $ 3.74 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.74 Million | -20.44% |
| 2025 | $4.71 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of VivoSim Labs, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.74 Million USD |
| MoneyControl | $3.74 Million USD |
| MarketWatch | $3.74 Million USD |
| marketcap.company | $3.74 Million USD |
| Reuters | $3.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more